Methods: 35 patients with early rheumatoid arthritis – below 12 months from the onset, naive for DMARDs, underwent clinical standard examination as well as serum determinations for CRP, RF, anti-CCP2 antibodies and VEGF. The gene discussed is AGBL2; the disease is rheumatoid arthritis.